Ebisumoto Koji, Sakai Akihiro, Okami Kenji, Sugimoto Ryousuke, Saito Kosuke, Iida Masahiro
Department of Otolaryngology-Head and Neck Surgery, Tokai University, School of Medicine, Isehara 259-1193, Japan.
Case Rep Otolaryngol. 2013;2013:806284. doi: 10.1155/2013/806284. Epub 2013 Sep 15.
Small cell carcinoma (SmCC) most commonly occurs in the lung and rarely arises from the head and neck region. Further, composite SmCC is extremely rare. Therefore, no postoperative treatment strategy has been established. We report a 59-year-old male patient referred to our outpatient clinic for further examination and treatment of a laryngeal tumor. Biopsy from the tumor revealed squamous cell carcinoma (SCC). The preoperative diagnosis was supraglottic SCC (T3N2bM0), and total laryngectomy and bilateral neck dissection were performed. Pathological examination revealed 2 individual cancer components: SmCC and SCC. Postoperative chemoradiotherapy (2 courses of cisplatin (CDDP) and etoposide (VP-16)) was indicated. Following the postoperative chemoradiotherapy, 2 courses of adjuvant chemotherapy were administered. The patient is currently alive with no evidence of disease at 36 months following the completion of therapy. Postoperative chemoradiotherapy and adjuvant chemotherapy are optimal treatment strategies for laryngeal composite SmCC.
小细胞癌(SmCC)最常见于肺部,很少起源于头颈部区域。此外,复合性小细胞癌极为罕见。因此,尚未确立术后治疗策略。我们报告一名59岁男性患者,因喉部肿瘤前来我院门诊进行进一步检查和治疗。肿瘤活检显示为鳞状细胞癌(SCC)。术前诊断为声门上型鳞状细胞癌(T3N2bM0),遂行全喉切除术及双侧颈部淋巴结清扫术。病理检查发现两种独立的癌成分:小细胞癌和鳞状细胞癌。术后进行了化疗放疗(2个疗程的顺铂(CDDP)和依托泊苷(VP - 16))。术后化疗放疗后,又进行了2个疗程的辅助化疗。在治疗完成36个月后,患者目前存活,无疾病证据。术后化疗放疗和辅助化疗是喉复合性小细胞癌的最佳治疗策略。